Evome Medical Technologies Inc. (the “
Company” or
“
Evome”) (TSXV: EVMT) highlights its low-CapEx
plan for growing revenue in an updated corporate presentation now
available at www.evomemedical.com/investor.
The presentation, to be used during investor
meetings planned for next month in New York, Vancouver, Montreal,
and Toronto, highlights recent progress to stabilize the business
and generate consistent positive Adjusted EBITDA1, as well as a
fresh growth strategy based on leveraging the Biodex® brand of its
core business, Biodex Medical Systems, Inc.
(“Biodex”), and its more than 15,000 customers
served over the past 30 years. The revenue strategy features
expanding the product portfolio with the addition of novel
products, largely sourced from single-product companies that are
privately owned and undercapitalized, and are suffering from
limited distribution, both domestically and internationally.
Growth Plan Highlights
- Focus on Core
Expertise: Prioritize clinical devices, therapeutic
modalities and digital applications that complement Biodex's®
strengths in orthopedic, neurologic and cardiopulmonary
rehabilitation.
- Global Distribution
Network: Utilize Biodex’s® extensive network of 52
distributors reaching more than 70 countries to maximize market
reach and penetration.
- Brand Leverage:
Capitalize on the Biodex® brand, widely recognized as a leader in
isokinetic physical therapy, to drive brand trust and product
sales.
- Strategic
Acquisitions: Aim to acquire or license one new product
per quarter, beginning in Q4 of this year.
"The Biodex® brand and its large customer
database are the keys to our success and future growth,” said Mike
Seckler, CEO. “Our customers demand new and novel devices and
services, and they trust our brand and value their long-standing
relationships with us. As such, we are well-positioned to make
other products available to expand their clinical offering and keep
them competitive. At the same time, there are hundreds of small,
private companies who are selling a single product with limited
U.S. distribution and no international reach. By acquiring or
licensing these products, we can brand them as Biodex® and make
them available to our customers worldwide.”
“From a financial perspective, our plan is based
on using very limited capital thereby reducing our need for debt or
equity financing to grow revenue,” he added. “Our plan is to
leverage existing relationships and invest in sales and marketing,
rather than pursue capital-intensive product development."
Prior to joining Evome, Mr. Seckler served as VP
of Global Marketing at Ferring Pharmaceuticals, a
multibillion-dollar company, where he led revenue growth and
international distribution and was responsible for evaluating
potential mergers, acquisitions and business development
initiatives.
Conference Call
As a reminder, the Company will hold a
conference call on Monday, August 19, 2024, at 2:00 PM Eastern time
(11:00 AM Pacific time). The call will be hosted by Mike Seckler,
CEO, and Gordon Bean, CFO. Please register via the link below to
attend.
Date: Monday, August 19, 2024Time: 2:00 PM
Eastern time (11:00 AM Pacific time)Link for attendees to register:
https://register.gotowebinar.com/register/656455062393989723
About Evome
Evome Medical Technologies Inc. (TSXV: EVMT)
specializes in human performance and rehabilitative solutions
achieved through strategic acquisitions and leveraging the
intellectual properties of specialized companies under its
wholly-owned subsidiaries. Evome’s goal is to create a large,
broad-based medical device company with global reach. For more
information visit www.evomemedical.com.
Biodex® is a leader in innovative rehabilitation
solutions, recognized for its advanced product line serving
orthopedic, sports medicine and neurorehabilitation needs. Renowned
for its precision and durability, Biodex® offers advanced equipment
such as balance and mobility systems, isokinetic testing devices
and comprehensive upper extremity rehabilitation tools. With a
presence in over 70 countries and partnerships with 52
distributors, Biodex® continues to drive advancements in patient
care through a strong commitment to research, education and
technology integration.
For Additional Information:
Mike Seckler Chief Executive
Officerinfo@evomemedical.com
For Media and Investor
Relations:
irlabsAlyssa BarryPrincipal and Co-Founder1
(833) 947-5227
Additional Information
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
There can be no assurance that any acquisitions
(including the proposed acquisitions disclosed herein) will be
completed or the sale price or timing of any acquisition.
Completion of any transaction will be subject to, amongst other
things, negotiation and execution of definitive agreements, and
applicable director, shareholder and regulatory approvals.
Certain statements contained in this press
release constitute "forward-looking information" within the meaning
of applicable Canadian securities laws. These statements can be
identified by the use of forward-looking terminology such as
“expects” “believes”, “estimates”, "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan", and
"anticipate", and similar expressions as they relate to the
Company, including the entirety of the Company’s growth plan and
its potential results. All statements other than statements of
historical fact may be forward-looking information. Such
statements reflect the Company's current views and intentions with
respect to future events, and current information available to the
Company, and are subject to certain risks, uncertainties and
assumptions, including: the Company successfully identifying
sellers and negotiating and closing transactions in an effort to
acquire or license products at a certain pace per quarter. The
Company cautions that the forward-looking statements contained
herein are qualified by important factors that could cause actual
results to differ materially from those reflected by such
statements. Such factors include but are not limited to the
general business and economic conditions in the regions in
which the Company operates; the ability of the Company to execute
on key priorities, including the successful completion of
acquisitions, business retention, and strategic plans and to
attract, develop and retain key executives; difficulty integrating
newly acquired businesses; ongoing or new disruptions in the
supply chain, the extent and scope of such supply chain
disruptions, and the timing or extent of the resolution or
improvement of such disruptions; the ability to implement
business strategies and pursue business opportunities;
disruptions in or attacks (including cyber-attacks) on the
Company’s information technology, internet, network access or other
voice or data communications systems or services; the evolution
of various types of fraud or other criminal behavior to which
the Company is exposed; the failure of third parties to comply with
their obligations to the Company or its affiliates; the impact
of new and changes to, or application of, current laws and
regulations; granting of permits and licenses in a highly
regulated business; the overall difficult litigation
environment, including in the United States; increased competition;
changes in foreign currency rates; increased funding costs
and market volatility due to market illiquidity and competition for
funding; the availability of funds and resources to pursue
operations; critical accounting estimates and changes to
accounting standards, policies, and methods used by the
Company; the occurrence of natural and unnatural catastrophic
events and claims resulting from such events; as well as
those risk factors discussed or referred to in the Company’s
disclosure documents filed with United States Securities and
Exchange Commission and available at www.sec.gov, and with the
securities regulatory authorities in certain provinces of Canada
and available at www.sedarplus.com. Should any factor affect
the Company in an unexpected manner, or should assumptions
underlying the forward-looking information prove incorrect, the
actual results or events may differ materially from the results
or events predicted. Any such forward-looking information is
expressly qualified in its entirety by this cautionary
statement. Moreover, the Company does not assume responsibility
for the accuracy or completeness of such forward-looking
information. The forward-looking information included in this
press release is made as of the date of this press release and
the Company undertakes no obligation to publicly update or revise
any forward-looking information, other than as required by
applicable law.
This press release refers to “Adjusted EBITDA”
which is a non-GAAP and non-IFRS financial measure that does not
have a standardized meaning prescribed by GAAP or IFRS. The
Company’s presentation of this financial measure may not be
comparable to similarly titled measures used by other companies.
This non-GAAP financial measure assists the Company’s management
in comparing its operating performance over time because certain
items may obscure underlying business trends and make comparisons
of long-term performance difficult, as they are of a nature and/or
size that occur with inconsistent frequency or relate to discrete
acquisition plans that are fundamentally different from the
ongoing operating plans of the Company. The Company’s management
also believes that presenting this measure allows investors to
view the Company’s performance using the same measures that the
Company uses in evaluating its financial and business performance
and trends. “Adjusted EBITDA” is defined as net loss excluding
interest expense, provision for income taxes, depreciation of
property and equipment, amortization of right-of-use asset,
amortization of intangible asset, foreign exchange (loss) gain,
other income, provision for impairment, change in fair value of
contingent consideration, transaction costs, gain/loss on sale of
business and stock-based compensation.
1 Non-GAAP financial measure or ratio. See "Additional
Information" below.
Evome Medical Technologies (TSXV:EVMT)
過去 株価チャート
から 10 2024 まで 11 2024
Evome Medical Technologies (TSXV:EVMT)
過去 株価チャート
から 11 2023 まで 11 2024
